ERBB2 and cancer: The principal possibility of the two-stage delivery of an active agent to the cancer cells was shown using the example of recombinant mini-antibodies, HER2/neu specific to the cancer surface antigen and conjugated with barstar, and a visualization component such as a recombinant fluorescent protein - EGFP - conjugated to barnase [31].